Direct-to-consumer prescription drug advertising in Canada: Permission by default?

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 5, 2003, Pages 425-427

  Gardner, David M ^a,c   Mintzes, Barbara ^b   Ostry, Aleck ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; CANADA; CONSUMER; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; NOTE; PRESCRIPTION; RISK BENEFIT ANALYSIS;

EID: 0042888750     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (31)

1. Silversides A. Direct-to-consumer prescription drug advertisements getting bolder. CMAJ 2001;165(4):462.
2. Health Products and Food Branch, Health Canada. Direct-to-consumer advertising of prescription drugs [discussion document]. 1999 Apr 6. Available: www.hc-sc.gc.ca/hpfb-dgpsa/oria-bari/99-04-14_3_e.html (accessed 2003 July 30).
3. Food and Drugs Act. Regulation C.01.044. Available: htrp://lois.justice.gc.ca/en/F-27/C.R.C.-c.870/125114.html (accessed 2003 Aug 5).
4. Michols DM. The distinction between advertising and other activities [policy statement]. Ottawa: Health Canada, Therapeutic Products Programme; 1996. Available: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/advsactv_e.html (updated 2003 Jan 30) (accessed 2003 July 30).
5. Rowsell LB. Advertising campaigns of branded and unbranded messages [policy statement]. Ottawa: Health Canada, Therapeutic Products Directorate; 2000. Available: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adv_campaign_e.html (updated 2003 Jan 30) (accessed 2003 June 23).
6. Mintzes B. The truth, the half truth, and nothing like the truth. Regulation of drug promotion in Canada. In: Barer ML, McGral KM, Cardiff K, Wood L, Green CJ, editors. Tales from the other drug wars. Papers from the 12th Annual Health Policy Conference; 1999 Nov 26; Vancouver. Vancouver: Centre for Health Services and Policy Research, University of British Columbia; 1999. Available: www.chspr.ubc.ca//misc/drugwars2.pdf (accessed 2003 July 30).
7. CBC-TV Undercurrents "The battle over a drug ad." [Transcript, Canadian NewsDisc]. 2001 Feb 4.
8. Letter from Bérubé A, Chief, Therapeutics Products Inspection Division, Bureau of Compliance and Enforcement, Health Canada, to J. Halmost-Stark, Director, Regulatory. Affairs. Wyeth-Ayerst Canada, re: Alesse advertising campaign. 2000 Nov 2.
9. National Institute for Health Care Management Foundation. Prescription drugs and mass media advertising, 2000 [report]. Washington: The National Institute for Health Care Management Research and Educational Foundation; 2001. Available: www.nihcm.org/DTCbrief2001.pdf (accessed 2003 July 30).
10. Gale EAM. Lessons from the glitazones: a story of drug development. Lancet 2001;357:1870-5.
11. Willman D. How a new policy led to seven deadly drugs. Los Angeles Times 2000 Dec 20; Sect A:1.
12. Mintzes B. Blurring the boundaries: new trends in drug promotion. In: Promotion targeting consumers. Amsterdam: HAI-Europe; 1998. Available: www.haiweb.org/pubs/blurring/blurring.intro.html (accessed 2003 July 30).
13. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct-to-consumer advertisements for prescription drugs: What are Americans being sold? Lancet 2001;358:1141-6.
14. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
15. Calfee J. Public policy issues in direct-to-consumer advertising of prescription drugs. J Public Policy Mark 2002;21:174-93.
16. Lyles A. Direct marketing of pharmaceuticals to consumers. Annu Rev Public Health 2002;23:73-91.
17. Holmer AF. Direct-to-consumer advertising - strengthening our health care system. N Engl J Med 2002;346:526-8.
18. Bell RA, Wilkes MS, Kravitz RL. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract 2000;49:1092-8.
19. Lexchin J, Mintzes B. Direct-to-consumer advertising of prescription drugs: The evidence says no. J Public Policy Market 2002;21:194-201.
20. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Affairs 2003:W3(Web exclusive):82-95. Available: www.healthaffairs.org/WebExclusives/Weissman_Web_Excl_022603.htm (accessed 2003 Jul 29).
21. Bodenheimer T. Two advertisements for TV drug ads. Health Affairs 2003:W3(Web exclusive):112-5. Available: www.healthaffairs.org/WebExclusives/Bodenheimer_Web_Excl_022603.htm. (accessed 2003 Jul 29).
22. Slaughter E, Schumacher M. Prevention's international survey on wellness and consumer reactions to DTCA of Rx drugs. Emmaus (PA): Prevention Magazine, Rodale Press; 2000/01.
23. Center for Drug Evaluation and Research, Food and Drug Administration. Attitudes and behaviors associated with direct-to-consumer (DTC) promotion of prescription drugs. Rockville (MD): The Centre; 1999. Available: www.fda.gov/cder/ddmac/dtctitle.htm (accessed 2003 July 30).
24. Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002;324:278-9.
25. Lexchin J. Should doctors be prescribing new drugs. Int J Risk Saf Med 2002;15:213-22.
26. Prescription drug expenditures in 2001: another year of escalating costs. Washington: The National Institute for Health Care Management; 2002. Available: www.nihcm.org/spending2001.pdf (accessed 2003 June 12).
27. Drake D, Uhlman M. Making medicine, making money. Kansas City (MO): Andrews and McMeel; 1993.
28. Kaitin K, Phelan NR, Raiford D, Morris B. Therapeutic ratings and end-of-phase II conferences: initiatives to accelerate the availability of important new drugs. J Clin Pharmacol 1991;31:17-24.
29. Patented Medicine Prices Review Board. Annual Report 2000. Ottawa: Supply and Services Canada; 2000. Available: www.pmprb-cepmb.gc.ca/english/View.asp?x=113&mp=91 (accessed 2003 July 30).
30. A look back at 2000: overabundance and deregulation. Prescrire Int 2001;10:52-4.
31. McGregor G. Ban on drug ads to stay: McLellan. Minister refuses to loosen regulations despite lobbying by manufacturers, media. Ottawa Citizen 2002 Mar 23;Sect A:7.